Lonza has been a dominant player in contract development and manufacturing for decades. We think its outlook is bright, especially as drug manufacturing becomes more complex, with biologics and specialized modalities like cell and gene therapies playing larger roles in the overall mix.
The pharma biotech and nutrition segment is a sticky business with long-term contracts and high switching costs for its customers.
Lonza is vulnerable to facility closures, whether from natural disasters or manufacturing issues, as a warning letter from the FDA can result in manufacturing delays or closures.
|
Metric
|
LONN
|
02269
|
SFZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 34.28 | 35.59 | 18.14 |
Price/Book Value | 4.82 | 4.35 | 3.11 |
Price/Sales | 6.21 | 8.87 | 2.30 |
Price/Cash Flow | 20.03 | 24.07 | 13.02 |
|
Metric
|
LONN
|
02269
|
SFZN
|
|---|---|---|---|
Quick Ratio | 0.59 | 2.64 | 1.36 |
Current Ratio | 1.66 | 3.32 | 3.45 |
Interest Coverage | 9.29 | 67.52 | 24.55 |
|
Metric
|
LONN
|
02269
|
SFZN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.27% | 10.38% | 7.56% |
Return on Equity (Normalized) | 13.97% | 14.65% | 15.73% |
Return on Invested Capital (Normalized) | 9.75% | 11.25% | 10.10% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|PkMX@ww | LOCK|X@t | $241B | |||
| Danaher Corp
DHR
| LOCK|$kgD&#% | LOCK|zMN | $149B | |||
| Agilent Technologies Inc
A
| LOCK|wp@@H>$B | LOCK|QKR | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|<b?$Jq> | LOCK|^>cZD | $43B | |||
| Waters Corp
WAT
| LOCK|m?LT@@ | LOCK|%@ | $42B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|<^N>^%% | LOCK|>b | $41B | |||
| Illumina Inc
ILMN
| LOCK|$Rz?jh | LOCK|Xw<Z | $40B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|k@h%Rb!w | LOCK|?VWN | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|zb!@Wf | LOCK|@^TP | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|<nhQM!#x | LOCK|GFFcR | $25B |
United States